Precision radiation aims to stop lung cancer return after surgery

NCT ID NCT06008730

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests proton beam radiation therapy in 20 adults with non-small cell lung cancer that has spread to chest lymph nodes (N2) and has been surgically removed. Proton therapy targets cancer cells while sparing healthy tissue, potentially reducing recurrence risk. Researchers will monitor side effects and survival over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton beam radiation therapy
What this could lead to: If successful, this could show that proton therapy is a safer and effective option after lung cancer surgery, potentially reducing recurrence with fewer side effects than standard radiation.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The main focus is on safety, not yet on proving long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE LUNG NON-SMALL CELL CARCINOMA

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.